JP2017526931A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526931A5
JP2017526931A5 JP2017513644A JP2017513644A JP2017526931A5 JP 2017526931 A5 JP2017526931 A5 JP 2017526931A5 JP 2017513644 A JP2017513644 A JP 2017513644A JP 2017513644 A JP2017513644 A JP 2017513644A JP 2017526931 A5 JP2017526931 A5 JP 2017526931A5
Authority
JP
Japan
Prior art keywords
haah
exosomes
item
exosome
magnetic beads
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017513644A
Other languages
English (en)
Japanese (ja)
Other versions
JP6669731B2 (ja
JP2017526931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049976 external-priority patent/WO2016040941A1/en
Publication of JP2017526931A publication Critical patent/JP2017526931A/ja
Publication of JP2017526931A5 publication Critical patent/JP2017526931A5/ja
Application granted granted Critical
Publication of JP6669731B2 publication Critical patent/JP6669731B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017513644A 2014-09-12 2015-09-14 がん患者由来のヒト血清のエクソソーム画分からのアスパルチル（アスパラギニル）ベータヒドロキシラーゼ（ｈａａｈ）の回収 Expired - Fee Related JP6669731B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462049582P 2014-09-12 2014-09-12
US62/049,582 2014-09-12
PCT/US2015/049976 WO2016040941A1 (en) 2014-09-12 2015-09-14 Recovery of aspartyl (asparaginyl) beta hydroxylase (haah) from an exosomal fraction of human sera from cancer patients

Publications (3)

Publication Number Publication Date
JP2017526931A JP2017526931A (ja) 2017-09-14
JP2017526931A5 true JP2017526931A5 (enExample) 2018-09-06
JP6669731B2 JP6669731B2 (ja) 2020-03-18

Family

ID=55454511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513644A Expired - Fee Related JP6669731B2 (ja) 2014-09-12 2015-09-14 がん患者由来のヒト血清のエクソソーム画分からのアスパルチル（アスパラギニル）ベータヒドロキシラーゼ（ｈａａｈ）の回収

Country Status (5)

Country Link
US (2) US20160077098A1 (enExample)
EP (1) EP3191841A4 (enExample)
JP (1) JP6669731B2 (enExample)
CA (1) CA2961004A1 (enExample)
WO (1) WO2016040941A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190049455A1 (en) * 2017-08-11 2019-02-14 Panacea Pharmaceuticals Inc. HAAH and MMP-9 are Complementary Cancer Biomarkers and Predictors of Metastasis when Combined
CN107907689A (zh) * 2017-10-10 2018-04-13 北京大学 外泌体蛋白cd5l的检测方法
CN111269986A (zh) * 2020-03-24 2020-06-12 江西惠肽生物科技有限公司 外泌体中asph基因在肺癌早期诊断试剂盒中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
WO2007087646A2 (en) * 2006-01-27 2007-08-02 Panacea Pharmaceuticals, Inc. Methods of diagnosing, predicting therapeutic efficacy and screening for new therapeutic agents for leukemia
US20090298097A1 (en) * 2007-07-17 2009-12-03 Harris Pamela J Methods for the diagnosis of lung cancer
EP3181705A1 (en) * 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
US20130178383A1 (en) * 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
CN103237901B (zh) * 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
CA2827894A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
KR20140136805A (ko) * 2013-05-21 2014-12-01 건국대학교 산학협력단 신규한 인간 엑소좀 단백질 및 그 용도

Similar Documents

Publication Publication Date Title
CA2844033C (en) Method for detecting pancreatic cancer
EP4582812A3 (en) Assays for detecting the presence or amount of an anti-drug antibody
MX361502B (es) Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano.
JP2012073260A5 (enExample)
JP2014508298A5 (enExample)
EA201792289A1 (ru) Способы обнаружения агглютинации и композиции для их осуществления
MX2016001573A (es) Ensayos para timp2 con mejor rendimiento en muestras biológicas.
NZ609824A (en) Immunochromatography devices, methods and kits
ZA202002415B (en) Detection of symmetrical dimethylarginine
JP2016520846A5 (enExample)
TW200741203A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
JP2015502547A5 (enExample)
WO2013049704A3 (en) Method and system of particle-phage epitope complex
MX2014010068A (es) Metodos y sistemas para amplificacion de señal de bioensayos.
JP2017526931A5 (enExample)
JP2018528441A5 (enExample)
JP2015531487A5 (enExample)
WO2011116209A3 (en) Using phage epitopes to profile the immune response
WO2018068064A3 (en) Mycobacterium tuberculosis proteins in diagnostic assays and devices for tuberculosis detection and diagnosis
TWI800483B (zh) 抗人類血紅素單株抗體或抗體套組、抗人類血紅素單株抗體固定化不可溶性載體粒子、及使用其等之測定試劑或測定方法
WO2014151079A8 (en) Ratio based biomarkers and methods of use thereof for the detection and prognosis of cancer
MX2016017048A (es) Inmunoensayo reactivo y colaborativo potenciado por enzimas (ceer) usando citometria de flujo.
JP2018519525A5 (enExample)
WO2018226098A3 (en) METHODS OF TYPING NEUROLOGICAL DISORDERS AND CANCER, AND DEVICES THEREOF
PH12019500151A1 (en) Immunofiltration method and immunofiltration device for serum fucose protein assay